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Abstract
Background: The management of Barrett's esophagus (BE), particularly high grade dysplasia
(HGD), is an area of much debate and controversy. Surgical esophagectomy, intensive endoscopic
surveillance and mucosal ablative techniques, especially photodynamic therapy (PDT), have been
proposed as possible management strategies. The purpose of this study was to determine the
health related quality of life associated with Barrett's esophagus and many of the pivotal health
states associated with Barrett's HGD management.
Methods: 20 patients with Barrett's esophagus were enrolled in a pilot survey study at a large
urban hospital. The utility of Barrett's esophagus without dysplasia (current health state) as well as
various health states associated with HGD management (hypothetical states as the subject did not
have HGD) were measured using a validated health utility instrument (Paper Standard Gamble).
These specific health states were chosen for the study because they are considered pivotal in
Barrett's HGD decision making. Information regarding Barrett's HGD was presented to the subject
in a standardized format that was designed to be easily comprehendible.
Results: The average utility scores (0–1 with 0 = death and 1 = perfect health) for the various
Barrett's esophagus associated states were: BE without dysplasia-0.95; Post-esophagectomy for
HGD with dysphagia-0.92; Post-PDT for HGD with recurrence uncertainty-0.93; Post-PDT for
HGD with recurrence uncertainty and dysphagia-0.91; Intensive endoscopic surveillance for HGD-
0.90.
Conclusion: We present the scores for utilities associated with Barrett's esophagus as well as
various states associated with the management of HGD. The results of our study may be useful in
advising patients and providers regarding expected outcomes of the various HGD management
strategies as well as providing utility scores for future cost-effectiveness analyses.
Background
Barrett's esophagus (BE) is a result of chronic reflux dis-
ease and is a risk factor for esophageal adenocarcinoma
[1] following a proposed dysplasia-carcinoma sequence:
intestinal metaplasia (BE); to low grade dysplasia (LGD);
to high grade dysplasia (HGD); to adenocarcinoma. Daily
symptoms of gastroesophageal reflux disease have been
reported in 7% of the population [2] and is of public con-
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cern because of the alarming rise in esophageal adenocar-
cinoma incidence in the past two decades [3].
Although surgical esophagectomy is considered by many
as the standard management for esophageal cancer in
those patients who are operative candidates, a consensus
regarding the optimal management of HGD does not
exist. Publications have reported a wide range 27–73% [4-
10] of missed and concomitant cancers when patients
with HGD detected by endoscopic biopsy undergo surgi-
cal resection. Advocates of surgery have therefore pro-
posed that all patients with HGD should undergo
prophylactic esophagectomy [11]. However, the morbid-
ity and mortality associated with surgical esophagectomy
is of considerable concern [12]. Furthermore, the largest
published study to date of more than 1000 patients with
over a 7 year period of follow-up found that the 'missed'
esophageal cancer rate in HGD was lower than previous
reports [13], further arguing that the risks of surgery may
outweigh the potential benefits and that endoscopic sur-
veillance may be a reasonable strategy.
Mucosal ablation is an area of much current investigation
and provides an intermediate option between surgery and
endoscopic surveillance, with the most data available for
photodynamic therapy (PDT). PDT is an endoscopic abla-
tive treatment that has successfully treated patients with
BE and early esophageal cancer or HGD who have tradi-
tionally been poor operative candidates for esophagec-
tomy [14]. Although larger studies demonstrating PDT's
long-term efficacy are not currently available, if proven
effective, the low mortality and morbidity associated with
PDT and the fact that patients can be treated on an outpa-
tient basis make it an attractive potential first-line therapy
of BE with HGD. Furthermore, a published cost-effective-
ness analysis [15] suggested PDT could be a preferred
strategy, but only if the quality of life after PDT was rela-
tively high. The purpose of this pilot study was to deter-
mine the utility of health states associated with Barrett's
esophagus and Barrett's HGD management, in order to
elucidate the outcomes of different management strate-
gies and inform clinical decision making. Utility assess-
ment is a particularly appealing quality of life measure
because it incorporates all aspect of health into a single
number (between 0 and 1) with the extreme endpoints of
death and perfect health [16].
Methods
Patients
Patients with documented (by histology) Barrett's esopha-
gus over the age of 18 who were either having an endos-
copy or a clinic visit within the Massachusetts General
Hospital (large, urban hospital) GI Associates' practice
were identified by one of the investigators using the prac-
tice's patient scheduling system. Subjects gave informed
consent prior to participation and received no remunera-
tion.
After permission was obtained from the patient's physi-
cian, the investigator invited the potential subject to par-
ticipate. A total of 26 patients were asked to participate in
this study and 20 completed the study. The institutional
review board overseeing human research at the Massachu-
setts General Hospital approved the study.
Patients recruited in the endoscopy unit (18/20) were
approached prior to their endoscopy, and if willing, a
future telephone appointment was made to administer
the questionnaire. The subject was also given written cop-
ies of the questionnaires (described in next section) in a
packet to take home for review prior to the telephone call.
Alternatively, if the subject was recruited in the outpatient
clinic (2/20), the questionnaire was administered in per-
son after the scheduled physician visit.
Regardless of the method used to administer the survey,
the investigator attempted to standardize the interview as
much as possible.
Patients with Barrett's esophagus were chosen for the
study because they would be familiar with endoscopic
surveillance and may have considered many of the issues
regarding HGD management, thereby making them an
informed and realistic patient population facing these
decisions. Although patients with HGD or prior HGD
were excluded, patients with prior LGD were included.
The description of the patient recruitment and separate
data acquired from these recruited subjects have been pre-
viously published [17]. However, the data presented in
this manuscript are the results of a new analysis using dis-
tinct data that have not yet been published (except in
abstract form) [18].
Study administration and materials
The standard gamble instrument is considered the gold
standard method for utility measurement [19]. To assess
utilities in our subjects with BE, we used a previously val-
idated paper version of the standard gamble [16,20]
(Appendix [see Additional file 1]).
After measuring the subjects' utility for their current
health state (Barrett's esophagus without dysplasia), each
enrolled patient was then asked to assess four hypotheti-
cal health states that might result from management strat-
egies for Barrett's HGD. These states included: 1) Post-
surgical esophagectomy for HGD without concern regard-
ing BE or dysplasia recurrence but with dysphagia; 2)
Post-successful PDT for HGD with concern about an
unknown chance of recurrence but no dysphagia; 3) Post-Health and Quality of Life Outcomes 2006, 4:45 http://www.hqlo.com/content/4/1/45
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successful PDT for HGD with concern about an unknown
chance of recurrence and with dysphagia; 4) Intensive
Endoscopic Surveillance (Appendix for complete descrip-
tions of all the health states [see Additional file 1]). Each
of these hypothetical health states was presented in a
standardized format including risks of BE and HGD recur-
rence, future endoscopic surveillance regimens and possi-
ble morbidity or side effects.
Table 1 presents the estimates for various aspects of the
strategies portrayed in the health state descriptions with
references to the published literature upon which they are
based. In constructing the descriptions of the various
health states, a careful balance was sought between accu-
rately portraying the medical complexities involved in
each state and minimizing "cognitive burden" (i.e., effort
required to perceive, think and remember) as described in
Furlong et al.'s guide to health state questionnaires [21]. A
summary in bullet format was provided for each health
state to help the subject keep the important factors in
mind while undergoing utility assessment.
In the standard gamble (SG) utility assessment method,
patients are offered an option such as an imaginary pill
that will result in either perfect health or death. The max-
imum amount of risk of death that a patient is willing to
assume for a chance at perfect health is determined and
used to derive the utility of the health state in question
[22]. The SG instrument was originally administered face-
to-face with trained interviewers, but the more recently
developed Paper Standard Gamble was developed and
validated so that instrument could be self-administered
[16]. In our study, although the Paper Standard Gamble
(Appendix [see Additional file 1]) was used, a study inves-
tigator provided each subject with directions regarding the
instrument and allowed the patient to ask questions,
either in person (2/20), or by telephone (18/20) during
utility measurements for each health state presented. All
surveys were administered by a single investigator (C.H.)
who tried, if it all possible, to limit the number of ques-
tions asked by subjects during the interview, in an attempt
to maintain study standardization.
On average, this portion of the questionnaire took
approximately 15 minutes to complete. At the end of the
interview, the interviewer qualitatively assessed the per-
ceived quality of the subject's comprehension on a scale of
1–3 (1-poor, 2-fair, 3-excellent).
The subject's demographic and clinical data were retrieved
from the patient's electronic medical record after the inter-
view was completed. The study instruments and algo-
rithm were tested and refined on four (non-patient)
subjects for feasibility and comprehension prior to use
with actual study subjects. The primary refinements that
resulted from this 'pre-testing' were further simplifications
of many of the medical terms used to describe the various
health states.
Data analysis
This was a descriptive, cross-sectional study where the
results are presented as average (mean and median) scores
with ranges and standard deviations. No statistical analy-
ses or power calculations were performed for this pilot
study.
Results
Clinical and demographic features
The mean age of the subjects in the study was 64.6 years
and 55% (11/20) were male. 20% of the subjects had
undergone a Nissen fundoplication surgery, 15% had a
history of dysphagia and 10% had a history of Barrett's
Table 1: References for characteristics of health states
Characteristic Patient Simplified Description Published Values References
Esophagectomy
Sx Success Rate "cured" Recurrence 0–2%/year* Rice [7], Ferguson [27]
Dysphagia Treatment "3 endoscopies" Headrick [28]
Endoscopic Dilation Perforation "1 in 200" >0.25%/dilation Bueno [29]
Follow-up Surveillance
EGD every year Hur [30]
Photodynamic Therapy
Recurrence Risk "chance of recurrence" Barham [31], Bonavina [32]
Dysphagia Treatment "3 endoscopies" Headrick [28]
Endoscopic Dilation Perforation "1 in 200" >0.25%/dilation Bueno [29]
Follow-up Surveillance
EGD every 3–6 months for 2 years and then yearly Hur [15]
Intensive Endoscopy
EGD every 3 months Sampliner [33]
Abbreviations: EGD-upper endoscopy; Sx-surgery; PDT-photodynamic therapy.Health and Quality of Life Outcomes 2006, 4:45 http://www.hqlo.com/content/4/1/45
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low grade dysplasia that subsequently regressed on fol-
low-up endoscopic biopsies (Table 2).
Questionnaire responses
The paper standard gamble utility scores are presented in
Table 3. The average (mean) utility score for the subjects'
actual health state (BE without dysplasia) was 0.95, with
0 representing death or the worst score and 1.0 represent-
ing the best score or perfect health. Utility scores elicited
for various hypothetical health states related to the differ-
ent management options associated with Barrett's HGD
were as follows: Post-esophagectomy with dysphagia =
0.92; Post-PDT without dysphagia = 0.93; Post-PDT with
dysphagia = 0.91. The state of undergoing intensive endo-
scopic surveillance as a management strategy for HGD
resulted in a quality of life utility of 0.90. As would be
expected, the utility scores for the HGD health states are
lower (or worse quality of life) than the BE without dys-
plasia score.
The average rating of the interview quality or subject com-
prehension graded by the interviewer was 2.75 with all
interviews rated either 2 or 3 (1–3 scale).
Discussion
We present estimates of utilities for Barrett's esophagus as
well as various health states associated with Barrett's HGD
management and therapy using the Paper Standard Gam-
ble instrument. Although other studies have analyzed
quality of life in patients with gastroesophageal reflux dis-
ease (GERD) and BE, our analysis is the first to present
utilities associated with many of the pivotal health states
associated with Barrett's HGD management.
Gerson et al. recently published the results of an analysis
which used a computer program to elicit utilities from
patients with GERD as well as a subset of patients who
also had BE [23]. The utilities derived from BE patients
using the standard gamble were 0.95 for patients on reflux
therapy and 0.93 for BE off of reflux therapy. Our BE with-
out dysplasia utility score is within the same range as this
separate and independent study, lending further credence
to both analyses' findings. Another study of fifteen
patients found that patients undergoing endoscopic sur-
veillance reported a reduced quality of life distinct from
their reflux symptoms [24]. Provenzale et al. [25] elicited
utilities using the time-trade-off technique to estimate the
quality of life after an esophagectomy and found a
median value of 0.97 (or 97% of perfect health). How-
ever, no published analysis to date report utilities for the
Barrett's HGD management states that we have studied
A limitation to the study was the relatively small sample
size. This is of particular concern as large variations in
quality of life were found among those who provided
scores for BE. The congruency in our BE without dysplasia
utility score and those of Gerson et al. [23] provides some
reassurance, although the utilities elicited for the hypo-
thetical states should be considered with some caution
until confirmed in a larger study. We also chose to include
patients who had a history of LGD, and although they
only comprised 10% of the subjects studied, these
patients could have a differing perspective of HGD.
Except for utilities scores for BE without dysplasia, the
other utilities were evaluated for hypothetical states.
Community or population utilities approximate societal
values, which can be estimated by sampling general soci-
ety. Especially if a disease or health state is rare, the soci-
etal value for a disease health state would be
Table 2: Patient Characteristics
Characteristics Mean Range
Age 64.6 49–77
Sex
Male 55%
Female 45%
Prior Nissen
Fundoplication 20%
History of dysphagia 15%
History of low grade dysplasia 10%
Table 3: Utilities Associated with Various Barrett's Esophagus Health States
Health State Mean (Median) Range SD
Actual Patient Health State
Barrett's esophagus (no dysplasia) 0.95 (0.98) 0.775–0.995 0.067
Hypothetical Patient Health States
Post-Esophagectomy with dysphagia 0.92 (0.96) 0.725–0.995 0.079
Post-PDT (no dysphagia) 0.93 (0.98) 0.550–0.995 0.107
Post-PDT with dysphagia 0.91 (0.96) 0.550–0.995 0.117
Intensive Endoscopic Surveillance 0.90 (0.95) 0.550–0.995 0.138
Abbreviations: PDT-photodynamic therapy.Health and Quality of Life Outcomes 2006, 4:45 http://www.hqlo.com/content/4/1/45
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approximated by interviewing individuals who probably
will not have the disease but would be asked to imagine a
specific health state and then to assign a value to it using
an instrument for this purpose [26]. In our study, the sub-
jects were not a random sampling of general society, but
of patients with BE without dysplasia. The hypothetical
utilities derived from these subjects are somewhere
between a population and patient perspective. We believe
they were an appropriate group to study particularly
because of their familiarity with Barrett's esophagus,
endoscopy and esophageal adenocarcinoma.
Although our study subjects all had BE and some famili-
arity with many aspects of the hypothetical health states
described, in order to present the information surround-
ing this clinical issue to participants who were presumed
not to have prior medical training, it was necessary to sim-
plify medical complexities to make it comprehendible
and also to limit cognitive burden (see Methods section).
The process of simplification could have theoretically led
to biases, which could have influenced the participants'
choices, which is a possible limitation to the study esti-
mates for the hypothetical utility scores. The possibility of
biases in these types of studies is, to a large part, unavoid-
able. However, the best efforts were made by the investi-
gators to construct simplified presentations that were
objective and based on published literature.
Conclusion
Our study findings confirm the BE without dysplasia util-
ity score previously reported [23] and provides utilities for
pivotal health states associated in the management of Bar-
rett's HGD. The results of this study can provide useful
guidance for estimates to be used in cost-effectiveness
analyses as well as guidance for designing larger Barrett's
esophagus quality of life assessment studies. Our findings
may also provide some preliminary data to aid both
patient care providers and patients in the clinical decision
making process regarding the optimal management of
Barrett's HGD.
Abbreviations
BE Barrett's esophagus;
EGD esophagogastroduodenoscopy;
HGD high grade dysplasia;
PDT photodynamic therapy.
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